Florida Medicaid spending on GLP-1 drugs

How much did Florida Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $128.1 million for GLP-1 drugs paid through Florida Medicaid in 2025, across at least 133,482 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 85 rows of 252, so these figures are floors.

Pharmacies were reimbursed at least $30.0 million for GLP-1 drugs paid through Florida Medicaid in 2026 (quarter 1 only, as posted so far), across at least 29,769 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 21 rows of 65, so these figures are floors.

By year and ingredient

2020at least $1,708,136No dataat least $1,443,675at least $2,922,505at least $16,326,316$168,801$82,282at least $22,651,714
2021at least $4,064,146No dataat least $1,525,082at least $28,834,571at least $7,542,367at least $219,052$86,854at least $42,272,072
2022at least $8,236,775at least $409,880at least $1,498,973at least $65,636,604at least $2,642,245at least $301,793$71,878at least $78,798,147
2023at least $31,773,295at least $6,671,315at least $1,851,437at least $68,826,119at least $1,367,048at least $227,396Suppressedat least $110,716,610
2024at least $74,999,570at least $10,162,333at least $919,527at least $35,533,168at least $406,091$140,597Suppressedat least $122,161,286
2025at least $86,896,108at least $15,928,696at least $344,015at least $24,768,544at least $64,837$77,509Suppressedat least $128,079,710
2026 (Q1)at least $17,354,440at least $8,446,997at least $25,984$4,112,406Suppressed$13,937Suppressedat least $29,953,764

By product, 2025

Ozempicat least $84,761,995at least 88,51111 of 35
Rybelsusat least $885,337at least 9239 of 23
Wegovy$1,248,7769750 of 20
Mounjaroat least $15,730,319at least 15,28621 of 57
Zepboundat least $198,377at least 19112 of 19
Liraglutide (generic name listing)at least $208,556at least 64410 of 29
SaxendaSuppressedSuppressed4 of 4
Victozaat least $135,460at least 2424 of 11
Trulicityat least $24,768,544at least 26,5446 of 38
Bydureon$45,320620 of 2
Byetta$19,517240 of 2
Exenatide (generic name listing)SuppressedSuppressed4 of 4
Soliqua$77,509800 of 4
XultophySuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $34,365,193at least 36,09121 of 63
Q2 2025at least $35,222,016at least 36,71823 of 64
Q3 2025at least $29,623,331at least 30,80821 of 63
Q4 2025at least $28,869,171at least 29,86520 of 62

By quarter, 2026 (posted so far)

Q1 2026at least $29,953,764at least 29,76921 of 65

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.